Analysts think CRVO stock price could increase by 73%
Apr 10, 2025, 11:25 AM
-4.81%
What does CRVO do
CervoMed, a Boston-based biotechnology company with 8 employees, focuses on developing neflamapimod for neurodegenerative diseases and is conducting the RewinD-LB Phase 2b trial for dementia with Lewy bodies. The drug aims to modify disease processes and improve synaptic dysfunction.
8 analysts think CRVO stock price will increase by 73.27%. The current median analyst target is $15.30 compared to a current stock price of $8.83. The lowest analysts target is $10.10 and the highest analyst target is $22.05.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
